Senescence Sensitivity of Breast Cancer Cells Is Defined by Positive Feedback Loop between CIP2A and E2F1
Open accessPublished version of a preprint
The DOI matches its Crossref record; 60 of the 62 references it cites were found in a registry or an index.
Abstract
Senescence induction contributes to cancer therapy responses and is crucial for p53-mediated tumor suppression. However, whether p53 inactivation actively suppresses senescence induction has been unclear. Here, we show that E2F1 overexpression, due to p53 or p21 inactivation, promotes expression of human oncoprotein CIP2A, which in turn, by inhibiting PP2A activity, increases stabilizing serine 364 phosphorylation of E2F1. Several lines of evidence show that increased activity of E2F1-CIP2A feedback renders breast cancer cells resistant to senescence induction. Importantly, mammary tumorigenesis is impaired in a CIP2A-deficient mouse model, and CIP2A-deficient tumors display markers of senescence induction. Moreover, high CIP2A expression predicts for poor prognosis in a subgroup of patients with breast cancer treated with senescence-inducing chemotherapy. Together, these results implicate the E2F1-CIP2A feedback loop as a key determinant of breast cancer cell sensitivity to senescence induction. This feedback loop also constitutes a promising prosenescence target for therapy of cancers with an inactivated p53–p21 pathway. Significance: It has been recently realized that most currently used chemotherapies exert their therapeutic effect at least partly by induction of terminal cell arrest, senescence. However, the mechanisms by which cell-intrinsic senescence sensitivity is determined are poorly understood. Results of this study identify the E2F1-CIP2A positive feedback loop as a key determinant of breast cancer cell sensitivity to senescence and growth arrest induction. Our data also indicate that this newly characterized interplay between 2 frequently overexpressed oncoproteins constitutes a promising prosenescence target for therapy of cancers with inactivated p53 and p21. Finally, these results may also facilitate novel stratification strategies for selection of patients to receive senescence-inducing cancer therapies. Cancer Discov; 3(2); 182–97. ©2013 AACR. This article is highlighted in the In This Issue feature, p. 125
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“it does not compromise normal mouse development or growth, except for a defect in spermatogenesis [11,22,23]”
From Oncoprotein CIP2A is stabilized via interaction with tumor suppressor PP2A/B56 (2017) · cites this paper as [11]
In the citing paper
“CIP2A deficiency inhibits MYC activity, and Her2-driven mammary tumorigenesis in vivo [11,22]”
From Oncoprotein CIP2A is stabilized via interaction with tumor suppressor PP2A/B56 (2017) · cites this paper as [11]
In the citing paper
“without lack of any detrimental normal tissue homeostasis effects in a CIP2A-deficient mouse model [11,22,23]”
From Oncoprotein CIP2A is stabilized via interaction with tumor suppressor PP2A/B56 (2017) · cites this paper as [11]
In the citing paper
“This is a very important finding because the therapeutic effects of inhibition of CIP2A protein expression have been validated by numerous studies [6 -8,10 -12,21].”
From Oncoprotein CIP2A is stabilized via interaction with tumor suppressor PP2A/B56 (2017) · cites this paper as [11]
In the citing paper
“therapeutic impact of inhibition of CIP2A protein expression has been validated by numerous studies across human cancer types18,20,21,23,33,34.”
From Structural mechanism for inhibition of PP2A-B56α and oncogenicity by CIP2A (2023) · cites this paper as [18]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
METABRIC Group, Curtis, C., Shah, S. P., Chin, S.-F., Turashvili, G., Rueda, O. M., Dunning, M. J., Speed, D., Lynch, A. G., Samarajiwa, S., et al. (2012) · Nature · doi:10.1038/nature10983 · Cited by 6,097
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661 · cited 1×
“Moreover, re-activation of wild-type p53 in MCF-7 human breast cancer cells with small-molecule inhibitors of Mdm2-p53 interaction, Nutlin-3 (31), or RITA (32), inhibited CIP2A expression both at mRNA and protein level (Figure 1D, E and Figure S2A,B).”
BackgroundSenescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas
Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., & Lowe, S. W. (2007) · Nature · doi:10.1038/nature05529 · Cited by 2,473 · cited 1×
“To study whether, in addition to p53 activation (10), the loss of CIP2A also suppresses tumorigenesis, we analyzed mammary tumor initiation and progression in the MMTV neu breast cancer mouse model crossed with CIP2AHOZ mice.”
BackgroundBRAFE600-associated senescence-like cell cycle arrest of human naevi
Michaloglou, C., Vredeveld, L. C. W., Soengas, M. S., Denoyelle, C., Kuilman, T., van der Horst, C. M. A. M., Majoor, D. M., Shay, J. W., Mooi, W. J., & Peeper, D. S. (2005) · Nature · doi:10.1038/nature03890 · Cited by 2,160
The essence of senescence: Figure 1.
Kuilman, T., Michaloglou, C., Mooi, W. J., & Peeper, D. S. (2010) · Genes & Development · doi:10.1101/gad.1971610 · Cited by 2,038
Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis
Chen, Z., Trotman, L. C., Shaffer, D., Lin, H.-K., Dotan, Z. A., Niki, M., Koutcher, J. A., Scher, H. I., Ludwig, T., Gerald, W., et al. (2005) · Nature · doi:10.1038/nature03918 · Cited by 1,993
Restoration of p53 function leads to tumour regression in vivo
Ventura, A., Kirsch, D. G., McLaughlin, M. E., Tuveson, D. A., Grimm, J., Lintault, L., Newman, J., Reczek, E. E., Weissleder, R., & Jacks, T. (2007) · Nature · doi:10.1038/nature05541 · Cited by 1,820 · cited 8×
“Immunohistochemical staining for Ki–67 and DcR2 and hematoxylin and eosin (H&E) staining were conducted as previously described (41).”
BackgroundInfluentialAdjuvant Docetaxel or Vinorelbine with or without Trastuzumab for Breast Cancer
Joensuu, H., Kellokumpu-Lehtinen, P.-L., Bono, P., Alanko, T., Kataja, V., Asola, R., Utriainen, T., Kokko, R., Hemminki, A., Tarkkanen, M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053028 · Cited by 1,403
Self-citationGuy, C. T., Webster, M. A., Schaller, M., Parsons, T. J., Cardiff, R. D., & Muller, W. J. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.22.10578 · Cited by 1,193
Therapy-induced senescence in cancer.
Ewald, J. A., Desotelle, J. A., Wilding, G., & Jarrard, D. F. (2010) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djq364 · Cited by 824 · cited 4×
“Notably, although traditionally considered as apoptosisinducing agents, most of the currently used chemotherapies exert their therapeutic effect at least partly by senescence induction (6, 7).”
BackgroundInfluential
Cited by
All roads lead to PP 2A: exploiting the therapeutic potential of this phosphatase
Sangodkar, J., Farrington, C. C., McClinch, K., Galsky, M. D., Kastrinsky, D. B., & Narla, G. (2016) · The FEBS Journal · doi:10.1111/febs.13573 · Cited by 312
Khanna, A., Pimanda, J. E., & Westermarck, J. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1994 · Cited by 154
“40% of unselected patient populations (8, 11, 16).”
BackgroundInfluentialSelf-citationPP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells
Kauko, O., O’Connor, C. M., Kulesskiy, E., Sangodkar, J., Aakula, A., Izadmehr, S., Yetukuri, L., Yadav, B., Padzik, A., Laajala, T. D., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aaq1093 · Cited by 149
Self-citationMechanisms and significance of therapy-induced and spontaneous senescence of cancer cells
Mikuła‐Pietrasik, J., Niklas, A. A., Uruski, P., Tykarski, A., & Książek, K. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03261-8 · Cited by 144
Vainonen, J. P., Momeny, M., & Westermarck, J. K. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abe2967 · Cited by 117
Self-citation
Metadata
- Authors
- Laine, A., Sihto, H., Come, C., Rosenfeldt, M. T., Zwolinska, A., Niemelä, M., Khanna, A., Chan, E. K., Kähäri, V.-M., Kellokumpu-Lehtinen, P.-L., Sansom, O. J., Evan, G. I., Junttila, M. R., Ryan, K. M., Marine, J.-C., Joensuu, H., & Westermarck, J.
- Affiliations
- Åbo Akademi University (FI)
- Authors' Affiliations: 1Turku Centre for Biotechnology, University of Turku and Åbo Akademi University, and 2Turku Doctoral Program of Biomedical Sciences, University of Turku; Departments of 3Pathology, 4Medical Biochemistry and Genetics, and 5Dermatology, University of Turku and Turku University Hospital, MediCity Research Laboratory, University of Turku, Turku, 6Laboratory of Molecular Oncology, Molecular Cancer Biology Program, Biomedicum, and 7Department of Oncology, Helsinki University Central Hospital, University of Helsinki, Helsinki; 8Institute of Biomedical Technology and 9Department of Oncology, University of Tampere and Tampere University Hospital, Tampere, Finland; 10The Beatson Institute for Cancer Research, Glasgow, United Kingdom; 11Laboratory for Molecular Cancer Biology, Center for Human Genetics and VIB11—Center for the Biology of Disease, VIB-KULeuven, Leuven, Belgium; 12Department of Oral Biology, University of Florida, Gainesville, Florida; and 13Department of Pathology and Helen Diller
- Corresponding author
- Westermarck, Jukka
- ORCID
- Venue
- Cancer Discovery
- Published
- 2013-02-01
- Volume
- 3
- Issue
- 2
- Pages
- 182-197
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- PMC
- PMC3572190
- OpenAlex
- W2099186537
- Cited by
- 130
- References
- 62
- Citations by year
- 2026: 4 · 2025: 6 · 2024: 2 · 2023: 15 · 2022: 7 · 2021: 12 · 2020: 10 · 2019: 8 · 2018: 13 · 2017: 10 · 2016: 7 · 2015: 17 · 2014: 9 · 2013: 10
- FWCI
- 9.95
- Type
- journal article
- Language
- en
- Update notices
- correction (2020-05-01)
- Open access
- green
- europepmc.org
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion)
- Funders
- Cancer Research UK (A10419, 12481, 15816)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
- Keywords
- cellular senescence, breast cancer, CIP2A, E2F1, positive feedback loop, p53 inactivation, p21, protein phosphatase 2A, senescence resistance, mammary carcinogenesis, prognostic factors
- MeSH terms
- Docetaxel, Vinorelbine, Animals, Antinematodal Agents, Autoantigens, Breast Neoplasms, Embryo, Mammalian, Female, Fibroblasts, Humans, Membrane Proteins, Vinblastine, Blotting, Western, Mammary Neoplasms, Animal, Tumor Suppressor Protein p53, Cellular Senescence, Mice, Knockout, Drug Resistance, Neoplasm, Reverse Transcriptase Polymerase Chain Reaction, Feedback, Physiological, Taxoids, HCT116 Cells, Cell Line, Tumor, Intracellular Signaling Peptides and Proteins, Cell Proliferation, E2F1 Transcription Factor, Cyclin-Dependent Kinase Inhibitor p21, Mice, MCF-7 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Senescence Sensitivity of Breast Cancer Cells Is Defined by Positive Feedback Loop between CIP2A and E2F1. https://app.cochat.ai/papers/10.1158/2159-8290.cd-12-0292
- The paper
- Laine, A., Sihto, H., Come, C., Rosenfeldt, M. T., Zwolinska, A., Niemelä, M., Khanna, A., Chan, E. K., Kähäri, V.-M., Kellokumpu-Lehtinen, P.-L., Sansom, O. J., Evan, G. I., Junttila, M. R., Ryan, K. M., Marine, J.-C., Joensuu, H., & Westermarck, J. (2013). Senescence Sensitivity of Breast Cancer Cells Is Defined by Positive Feedback Loop between CIP2A and E2F1. Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-12-0292
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.